A Prospective Study on Role of Supplemental Oral Calcium and Vitamin D in Prevention of Postthyroidectomy Hypocalcemia

Krishnan Ravikumar1,2, Dhalapathy Sadacharan2, Sankaran Muthukumar2,3, Thalavai Sundaram2, Selladurai Periyasamy2, R. V. Suresh2
1Department of Endocrine Surgery, Christian Medical College, Vellore; 2Department of Endocrine Surgery, Madras Medical College, Chennai; 3Department of Endocrine Surgery, Madurai Medical College, Madurai, Tamil Nadu, India

Abstract

Background: Postoperative transient hypocalcemia is sequelae of total thyroidectomy (TT), which is observed in up to 50% of patients. Routine oral calcium and Vitamin D supplementation have been proposed to prevent symptomatic hypocalcemia preventing morbidity and facilitating early discharge. Patients and Methods: A total of 208 patients with nontoxic benign thyroid disorders, undergoing TT, were serially randomized into four groups: Group A (no supplements were given), Group B (oral calcium - 2 g/day given), Group C (calcium and calcitriol - 1 mcg/day are given), and Group D (calcium, calcitriol, and cholecalciferol - 60,000 IU/day are given). Patients were monitored for clinical and biochemical hypocalcemia (serum calcium, [Sr. Ca] <8 mg/dl), along with serum intact parathormone (Sr. PTH) and magnesium 6 h after surgery and Sr. Ca every 24 h. Intravenous (IV) calcium infusion was started, if any of the above four groups exhibit frank hypocalcemia. Patients are followed up with Sr. Ca and Sr. PTH at 3 and 6 months. Results: All groups were age and sex matched. Hypocalcemia was observed in 72/208 (34.61%) cases. Incidence of hypocalcemia was higher in Group A (57.69%) and Group B (50%) compared to Group C (15.38%) and Group D (15.38%). Hypocalcemia necessitating IV calcium occurred in 31/208 (14.90%) patients. IV calcium requirement exceeded in Group A (26.92%) and Group B (23.07%) compared to Group C (5.76%) and Group D (3.84%). There was no statistical difference in basal levels of serum Vitamin D, calcium, magnesium, intact PTH, and 6 h after surgery. Permanent hypoparathyroidism developed in five patients on follow-up. Conclusion: Routine postoperative supplementation of oral calcium and Vitamin D will help in the prevention of postthyroidectomy transient hypocalcemia significantly. Preoperative Vitamin D levels do not predict postoperative hypocalcemia.

Keywords: Hypocalcemia, total thyroidectomy, Vitamin D

Introduction

Postoperative transient hypocalcemia is observed in one-third to one-half of patients undergoing total thyroidectomy (TT).1 It is now considered sequelae of TT rather than a complication. The incidence of permanent hypoparathyroidism is 3% or less.2 Majority of these transient hypocalcemia may not warrant long-term calcium and Vitamin D supplementation. However, in a significant proportion of these patients, supplemental calcium and Vitamin D either therapeutically or prophylactically may improve the quality of life, shorten the hospital stay, and promote early discharge. Literature is robust on the role of postoperative intact parathormone (iPTH) level in predicting transient and permanent hypocalcemia.3-5 Various factors contribute to postthyroidectomy hypocalcemia such as hypothermia, Vitamin D deficiency, thyrotoxic osteodystrophy, prolonged surgical time, ischemia of the parathyroids, devascularization, or inadvertent removal of parathyroids.6-7 Few prospective randomized trials exist in the literature on the benefits of prophylactic and routine supplementation of calcium and Vitamin D in prevention of transient hypocalcemia.8-10 This study is an attempt to fill in the lacunae on the impact of routine supplementation of oral calcium and Vitamin D and its efficacy in preventing the morbidity of temporary hypocalcemia and early safe discharge. In this study, we presume that combination of calcium and calcitriol is vital for preventing postoperative hypocalcemia.

Address for correspondence: Dr. Dhalapathy Sadacharan, Department of Endocrine Surgery, Madras Medical College, Park Town, Chennai - 600 003, Tamil Nadu, India. E-mail: drsdhalapathy@gmail.com

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

How to cite this article: Ravikumar K, Sadacharan D, Muthukumar S, Sundaram T, Periyasamy S, Suresh RV. A prospective study on role of supplemental oral calcium and Vitamin D in prevention of postthyroidectomy hypocalcemia. Indian J Endocr Metab 2017;21:498-503.

Access this article online

Quick Response Code:
Website: www.ijem.in
DOI: 10.4103/ijem.IJEM_402_16
Patients and Methods

This prospective randomized controlled study was conducted in the Department of Endocrine Surgery, Madras Medical College. This study was conducted between December 2013 and November 2014. Institutional Ethical Committee approval obtained as per requirements (Approval No. 46062014/ ECR/270/Inst./TN/2013).

Patients with nontoxic, benign thyroid disorders undergoing TT were included in the study. Exclusion criteria comprise patients with proven or suspicious of malignancy, hyperthyroidism, reoperative surgery, elevated renal parameters (serum creatinine - >1.2), patients already on supplemental calcium, and Vitamin D.

A total of 208 patients comprising 178 females and 30 males were enrolled in the study. Informed written consent was obtained from all patients. The patients were assigned into four groups using systematic sampling randomization method. Four is used as the sampling interval.

Group A is a control group in which no supplements were given; intervention was started only after the onset of clinical or biochemical hypocalcemia. In Group B, patients were started with supplemental oral calcium alone. Calcium carbonate tablets containing 2000 mg of elemental calcium were given in four daily divided doses. In Group C, patients were supplemented with oral calcium (2000 mg/day) and oral calcitriol (1,25-dihydroxyvitamin D3) 1 mcg/day in four divided doses. In Group D along with oral calcium and calcitriol, cholecalciferol (25-hydroxyvitamin D3 [25(OH) D3]) granules 60000 IU/day for 5 days were given. All these supplemental interventions were started 6 h after surgery.

The preoperative investigations include renal function test (blood urea and serum creatinine), thyroid function test (free T3, free T4 and thyroid-stimulating hormone [TSH]), serum calcium (Sr. Ca), Sr. magnesium (Sr. Mg), Sr. phosphorus, Sr. albumin, serum alkaline phosphatase (SAP), Sr. iPTH (Cobas e411; Roche Diagnostics, Tokyo), and Sr. 25(OH) D (DiaSorin; Liaison, von Hevesy-Strasse, Dietzenbach).

TT was performed in all the cases with a standardized technique as per the institution protocol. The procedures were carried out by one of the authors. An attempt was made to identify and preserve all four parathyroid glands. Parathyroid glands, if inadvertently devascularized or removed, were autotransplanted into sternocleidomastoid muscle immediately.

Sr. PTH, Sr. Ca, and Sr. Mg were measured after 6 h, and then, supplemental interventions were started for Groups B, C, and D as per the protocol. Sr. Ca was measured every 24 h for 5 days.

Patients were monitored for clinical and biochemical hypocalcemia and graded accordingly. Symptoms monitored for mild hypocalcemia are perioral numbness, tingling, paresthesiae of the distal extremities, and occasional muscle cramping. For moderate hypocalcemia, more severe muscle cramps and for severe hypocalcemia, tetanic muscle cramps, carpopedal spasm, seizures, life-threatening laryngospasm, and coma were considered.[3] Standard Chvostek’s and Trousseau’s sign were monitored in the postoperative period every 6th hourly.

Sr. Ca (corrected) <8.0 mg/dL is considered biochemical hypocalcemia. The cutoff values for mild, moderate, and severe hypocalcemia are 7.50–7.99, 7.00–7.49, and <7.0 mg/dL, respectively. Based on the immediate 6-h postoperative levels, PTH values were classified into above low normal range (>12 pg/ml) and deficient (≤12 pg/ml).

Intravenous (IV) calcium was administered for patients who had moderate and severe symptomatic hypocalcemia irrespective of biochemical calcium values. Patients who had mild symptomatic hypocalcemia were managed with oral calcium and Vitamin D. Patients who were asymptomatic, in spite of biochemical hypocalcemia, were managed as per their group stratification.

Patients were followed up with Sr. Ca and Sr. PTH after 3 and 6 months of TT.

Statistical analysis was done using SPSS software (IBM-SPSS statistics 22.0; SPSS Inc., Chicago, IL, USA). Data were expressed as mean ± standard deviation (minimum–maximum). Multivariate analysis was done using logistic regression analysis. Categorical data analysis was done using Chi-square test and Student’s t-test. P <0.05 was considered statistically significant.

Results

In this present study, a total of 30 (14.4%) males and 178 (85.6%) females were assigned to four study groups using systematic sampling method. The mean age of the study population was 38.93 ± 11.02 (18–65) years, and all the four study groups were age (P = 0.250) and sex matched (P = 0.960). The mean values of various parameters in the preoperative period for the 208 patients include Sr. TSH (2.37 ± 1.16 µIU/ml), Sr. 25(OH) Vitamin D (20.79 ± 6.29 ng/ml), Sr. PTH (45.56 ± 9.00 pg/ml), Sr. Ca (9.27 ± 0.33 mg/dl), SAP (68.45 ± 17.18 U/L), Sr. Mg (2.06 ± 0.19 mg/dl), and Sr. phosphorus (3.45 ± 0.49 mg/dl).

There was no statistically significant difference between the mean values among the four study groups. The preoperative investigations of four groups are given in Table 1.

Intraoperatively, all the four parathyroid glands were identified and preserved with intact vascularity in 148 (71.1%), three glands in 57 (27.4%), and two glands in 3 (1.5%) cases. Autotransplantation of the parathyroid gland was done in 45 (21.6%) cases. The parathyroid gland preservation rate (P = 0.272) and autotransplantation of parathyroid glands (P = 0.191) were comparable among the four groups.

The mean 6-h postoperative values are as follows: Sr. Mg (1.90 ± 0.18 mg/dl), Sr. Ca (8.60 ± 0.57 mg/dl), and Sr. PTH (19.00 ± 9.10 pg/ml). The postoperative PTH values are >12 pg/ml in 109/208 (52.4%) and deficient (≤12 pg/ml) in 99/208 (47.6%). The 6-h postoperative values of...
Sr. Mg ($P = 0.942$), Sr. Ca ($P = 0.550$), and Sr. PTH ($P = 0.950$) were comparable between study groups.

The mean Sr. Ca values of the 208 study patients from the 1st postoperative day to consecutive 5 postoperative days were $8.57 \pm 0.75$ mg/dL, $8.72 \pm 0.65$ mg/dL, $8.93 \pm 0.47$ mg/dL, $9.12 \pm 0.42$ mg/dL, and $9.15 \pm 0.39$ mg/dL, respectively. On the first 3 postoperative days, the Sr. Ca values of Group A and B was significantly lower than Group C and D ($P > 0.05$), but the calcium levels between Group C and Group D was comparable between them ($P > 0.05$). The calcium values on day 4 and 5 were comparable between all the groups ($P > 0.05$). The distribution of postoperative values among the study groups were reported in Table 2 and Chart 1.

In our study, 72/208 (34.6%) patients developed hypocalcemia, but out of 72 biochemical hypocalcemic patients, only 67 had clinical hypocalcemia. Among 72 biochemical hypocalcemic cases, 41/72 (56.94%) had mild, 28/72 (38.88%) had moderate, and 3/72 (4.16%) had severe hypocalcemia. Out of 67 clinical hypocalcemic cases, 14/67 (20.89%) had mild, 31/67 (46.26%) had moderate, and 22/67 (32.83%) had severe hypocalcemia. The mean duration of onset of hypocalcemia was 27.43 $\pm$ 12.34 h. The duration of onset of hypocalcemia among four study groups is comparable ($P = 0.271$).

Out of the 72/208 hypocalcemic patients, 30/52 (57.69%) were in Group A, 26/52 (50.0%) in Group B, 8/52 (15.38%) in Group C, and 8/52 (15.38%) in Group D. Hypocalcemia was more in Group A and B compared to Group C and D patients ($P = 0.000$) There was no statistical difference in occurrence of hypocalcemia between individual groups, namely, between A and B as well as between C and D. IV calcium was required in 31/208 (14.9%), 14/52 (26.92%) Group A, 12/52 (23.07%) Group B, 3/52 (5.76%) Group C, and 2/52 (3.84%) Group D cases. Among this subset of hypocalcemic patients, 26/31 belong to Group A and B compared to 5/31 in Group C and D ($P = 0.001$).

Among the 99/208 patients who had deficient postoperative PTH (<12 pg/ml), only 68/99 had hypocalcemia. In the remaining 31/99 PTH deficient patients who did not have hypocalcemia, 15 were in Group C and 16 in Group D, none

### Table 1: Preoperative levels of various parameters among groups

| Parameter            | Group A ($n=52$) | Group B ($n=52$) | Group C ($n=52$) | Group D ($n=52$) | $P$  |
|----------------------|------------------|------------------|------------------|------------------|------|
| Age (years)          | 35.6±11.12 (18-60) | 40.8±11.55 (28-65) | 40.53±10.28 (22-55) | 38.78±11.01 (25-57) | 0.250 |
| Sex (male:female)    | 7:45             | 8:44             | 9:43             | 6:46             | 0.960 |
| Serum TSH (µU/mL)    | 2.05±0.83 (1.13-4.00) | 2.66±1.35 (1.23-6.20) | 2.18±1.41 (0.60-5.50) | 2.50±0.87 (1.40-1.44) | 0.094 |
| Serum PTH (pg/mL)    | 46.98±8.76 (29.70-59.96) | 45.64±7.88 (34.50-65.40) | 44.08±9.54 (29.78-65.40) | 45.56±9.87 (29.40-63.20) | 0.650 |
| Serum 25(OH) D (mg/mL) | 21.63±7.46 (12.42-40.10) | 20.58±5.68 (10.50-33.48) | 20.65±7.0 (12.60-37.50) | 20.32±4.91 (14.35-33.90) | 0.853 |
| SAP (IU/L)           | 68.46±18.66 (38.00-92.00) | 65.50±18.12 (39.00-99.00) | 72.63±15.65 (40.90-96.00) | 67.81±16.26 (34.00-112.00) | 0.502 |
| Serum Ca (mg/dL)     | 9.30±0.39 (8.42-9.98) | 9.27±0.37 (8.58-9.94) | 9.24±0.19 (8.98-9.60) | 9.29±0.34 (8.64-10.06) | 0.901 |
| Serum Mg (mg/dL)     | 2.08±0.17 (1.80-2.43) | 2.06±0.21 (1.78-2.52) | 2.09±0.18 (1.80-2.34) | 2.01±0.19 (1.76-2.30) | 0.455 |
| Serum phosphorus (mg/dL) | 3.54±0.52 (2.8-4.5) | 3.47±0.46 (2.8-4.4) | 3.25±0.35 (2.7-4.2) | 3.56±0.55 (2.8-4.8) | 0.530 |

Values: Mean±SD (range). $n$: Number of patients, 25(OH) D: 25-hydroxyvitamin D, TSH: Thyroid-stimulating hormone, SD: Standard deviation, PTH: Parathormone, SAP: Serum alkaline phosphatase, Ca: Calcium, Mg: Magnesium

### Table 2: Postoperative levels of various parameters among groups

| Parameters            | Group A ($n=52$) | Group B ($n=52$) | Group C ($n=52$) | Group D ($n=52$) | $P$  |
|-----------------------|------------------|------------------|------------------|------------------|------|
| Serum PTH at 6 h (pg/mL) | 18.71±10.39 (4.99-41.60) | 19.34±9.46 (1.80-41.24) | 19.51±8.67 (4.60-35.80) | 18.37±8.09 (4.23-36.37) | 0.950 |
| Serum Mg at 6 h (mg/dL) | 1.88±0.21 (1.60-2.16) | 1.90±0.18 (1.60-2.25) | 1.91±0.18 (1.60-2.25) | 1.91±0.15 (1.60-2.16) | 0.942 |
| Serum Ca at 6 h       | 8.51±0.50 (7.20-9.38) | 8.60±0.58 (6.96-9.40) | 8.57±0.62 (7.20-9.50) | 8.71±0.55 (7.20-9.50) | 0.550 |
| Serum Ca on I POD     | 8.20±0.73 (7.20-9.48) | 8.39±0.69 (7.16-9.42) | 8.71±0.72 (7.20-10.40) | 8.88±0.76 (7.30-10.40) | 0.005 |
| Serum Ca on II POD    | 8.48±0.64 (7.40-9.58) | 8.50±0.64 (7.36-9.50) | 8.86±0.54 (7.90-9.90) | 9.04±0.61 (7.76-9.90) | <0.001 |
| Serum Ca on III POD   | 8.79±0.42 (8.08-9.58) | 8.79±0.48 (7.96-9.62) | 9.06±0.48 (8.00-9.70) | 9.09±0.42 (8.16-9.70) | 0.008 |
| Serum Ca on IV POD    | 9.05±0.35 (8.58-9.78) | 8.99±0.43 (8.20-9.80) | 9.17±0.43 (8.20-9.90) | 9.25±0.43 (8.36-9.90) | 0.067 |
| Serum Ca on V POD     | 9.12±0.33 (8.50-9.70) | 9.04±0.41 (8.20-9.92) | 9.18±0.41 (8.20-9.90) | 9.27±0.39 (8.66-9.90) | 0.126 |

Values: Mean±SD (range). $n$: Number of patients, POD: Postoperative day, SD: Standard deviation, PTH: Parathormone, Mg: Magnesium, Ca: Calcium
from Group A and B ($P = 0.001$). The rate of hypocalcemia in the four assigned groups is given in Table 3.

Parathyroid autotransplantation was done in 45/208 (21.63%) cases comprising 15/52 (28.84%) in Group A, 8/52 (15.38%) in Group B, 16/52 (30.76%) in Group C, and 6/52 (11.53%) in Group D ($P = 0.191$). Among these 45 cases, 35 (77.77%) developed hypocalcemia, 15/15 (100%) in Group A, 8/8 (100%) in Group B, 8/16 (50%) in Group C, and 6/6 (66.66%) in Group D ($P = 0.191$). The mean Sr. PTH was lower in parathyroid autotransplanted cases (9.48 ± 3.04 pg/ml) than the remaining patients (21.67 ± 8.42 pg/ml) ($P = 0.001$) [Table 4].

On comparing the hypocalcemic and normocalcemic cohorts, all the preoperative parameters such as age, sex, and biochemical investigations were statistically insignificant. The postoperative Sr. PTH was lower in hypocalcemic (10.23 ± 3.62 pg/ml) than normocalcemic (23.60 ± 7.60 pg/ml) patients ($P = 0.001$), whereas the rate of parathyroid autotransplantation was higher in hypocalcemic (78.6%) than normocalcemic (21.4%) patients ($P = 0.003$). The comparisons between both the cohorts are given in Table 5.

Multivariate analysis performed on factors influencing hypocalcemia found that the preoperative Vitamin D levels did not influence the occurrence of hypocalcemia ($P = 0.702$). The factors such as parathyroid autotransplantation (odds ratio [OR] = 6.372) and postoperative Sr. PTH levels (OR = 18.10) had a high influence on occurrence of transient hypocalcemia [Table 6].

The follow-up levels of Sr. Ca and Sr. PTH after 3 and 6 months are comparable between all four groups. Out of 208 patients, 5 (2.40%) developed permanent hypoparathyroidism on follow-up, but no patients had

| Table 3: Parameters of hypocalcemia among four groups |
|-------------------------------------------------------|
| **Parameters**                                         | **Group A (n=52)** | **Group B (n=52)** | **Group C (n=52)** | **Group D (n=52)** | **P**  |
| Hypocalcemia, n (%)                                   | 30 (57.69)         | 26 (50)            | 8 (15.38)          | 8 (15.38)          | <0.001 |
| Intravenous Ca requirement, n (%)                     | 14 (26.92)         | 12 (23.07)         | 3 (5.76)           | 2 (3.84)           | 0.001  |
| Onset of hypocalcemia (h)                             | 26.39±10.83 (10.0-48.0) | 33.88±12.99 (8.0-60.0) | 20.80±4.55 (14.0-25.0) | 25.20±6.57 (20.0-36.0) | 0.074  |
| PT preserved (n)                                     | 3.59±0.615         | 3.78±0.42          | 3.63±0.49         | 3.78±0.42          | 0.272  |
| PT AT (%)                                             | 15/52 (28.84)      | 8/52 (15.38)       | 16/52 (30.76)     | 6/52 (11.53)       | 0.191  |

Values: Mean±SD (range). PT: Parathyroid, SD: Standard deviation, AT: Autotransplantation, Ca: Calcium

| Table 4: Comparison parathyroid autotransplanted cases and others |
|--------------------------------------------------------------|
| **Parameters**                                               | **PT AT (n=45)** | **No AT (n=163)** | **P**  |
| Serum PTH (pg/mL)                                           | 9.48±3.04 (4.60-14.20) | 21.67±8.42 (1.80-41.60) | 0.001  |
| Hypocalcemia (%)                                            | 35/45 (77.77)     | 37/163 (22.69)     | 0.001  |
| Onset of hypocalcemia (h)                                   | 24.64±7.27 (14.0-36.0) | 32.05±13.73 (10.0-60.0) | 0.031  |
| IV Ca requirement (%)                                       | 18/45 (40.0)      | 13/163 (7.97)      | <0.001 |
| Permanent Hypoparathyroidism (%)                            | 0/45 (0.0)        | 5/163 (3.06)       | 0.609  |

Values: Mean±SD (range). PT: Parathyroid, AT: Autotransplantation, SD: Standard deviation, PTH: Parathormone, IV: Intravenous, Ca: Calcium

| Table 5: Univariate analysis of hypocalcemic and normocalcemic patients |
|-----------------------------------------------------------------------|
| **Parameters**                                                         | **Hypocalcemia (n=72)** | **Normocalcemia (n=136)** | **P**  |
| Preoperative parameters                                                |                          |                          |        |
| Age (years)                                                           | 36.89±12.45              | 40.00±10.11              | 0.086  |
| Sex (male: female)                                                     | 12:42                    | 18:75                    | 0.201  |
| SAP (IU/L)                                                            | 67.13±18.26              | 69.14±16.64              | 0.739  |
| Serum TSH (µIU/mL)                                                     | 2.02±0.80                | 2.56±1.28                | 0.413  |
| Serum Mg (mg/dL)                                                       | 2.04±0.19                 | 2.07±0.19                | 0.160  |
| Serum phosphorus (mg/dL)                                               | 3.53±0.54                | 3.41±0.46                | 0.130  |
| Serum PTH (pg/mL)                                                     | 43.55±8.13               | 46.62±9.29               | 0.177  |
| Serum 25(OH) D (ng/mL)                                                 | 20.50±5.78               | 20.95±6.57               | 0.271  |
| Intraoperative parameters                                             |                          |                          |        |
| Parathyroids preserved (n)                                             | 3.43±0.58                | 3.83±0.37                | 0.136  |
| Parathyroid AT (%)                                                     | 22/28 (78.6)             | 6/28 (21.4)              | 0.003  |
| Postoperative parameters                                              |                          |                          |        |
| Serum PTH (pg/mL)                                                     | 10.23±3.62               | 23.60±7.60               | 0.001  |
| Serum Mg (mg/dL)                                                       | 1.88±0.19                | 1.91±0.18                | 0.131  |

Values: Mean±SD. SAP: Serum alkaline phosphatase, SD: Standard deviation, TSH: Thyroid-stimulating hormone, Mg: Magnesium, PTH: Parathormone, 25(OH) D: 25-hydroxyvitamin D, AT: Autotransplantation
parathyroid autotransplantation \( (P = 0.609) \). The data of follow-up were reported in Table 7.

**D**iscussion

Postoperative hypocalcemia is important sequelae of TT; it often increases the hospital stay and necessitates multiple blood samplings for serial monitoring of Sr. Ca or PTH levels.\[^9\] Symptomatic hypocalcemia usually develops as late as 24 h to several days after surgery. Postoperative supplementation of oral calcium and Vitamin D may be a useful approach in decreasing or preventing hypocalcemic morbidity and may be a prophylactic tool in the prevention of hypocalcemic crisis.\[^11\] In majority of cases, hypocalcemia resolves spontaneously, but it can remain prolonged in thyrotoxic osteodystrophy and persistent in devascularization and/or inadvertent removal of the parathyroid glands rendering the patient hypoparathyroid or parathyroid.\[^10\]

Thyrotoxicosis will alter calcium metabolism due to thyrotoxic osteodystrophy. The duration of hyperthyroidism and more importantly the duration of euthyroid state preceding definitive management of hyperthyroidism have a major impact on the postoperative timing and duration of hypocalcemia.\[^12\] Malignancy may warrant lymph node dissection, which would entail extensive dissection with increased probability of vascular compromise to the parathyroid end arteries and inadvertent parathyroid injury. This is more noticeable in patients undergoing central compartment lymph node dissection.\[^13\] The duration of surgery and associated hyperthermia might impact on the parathyroid function postoperatively by promoting vasospasm of these parathyroid end arteries. Abnormal renal function will result in altered PTH metabolism, interfering in PTH assay.\[^14\] Completion thyroidectomy or reoperative surgical procedures have been correlated with an increased risk for inadvertent parathyroidectomy because of fibrosis and operative difficulty.\[^15\] For the above said reasons, all these cases are excluded from the study.

In our study, the cohorts were age and sex matched \( (P = 0.250) \). Erbil et al. in a study of 130 patients reported that advancing age is a risk factor for hypocalcemia, but age did not have an impact between hypocalcemic and normocalcemic patients in our study.\[^15\]

Our results showed that the preoperative levels of Sr. 25(OH) Vitamin D did not correlate with postoperative Sr. Ca levels and were not a useful predictor of postoperative hypocalcemia which was similar to a study of 103 cases by Chia et al.,\[^16\] but Erbil et al. reported that the preoperative levels of Sr. 25(OH) Vitamin D is a major predictor of postthyroidectomy hypocalcemia.\[^15\]

McLeod et al. showed that postoperative PTH levels <12 pg/ml had 100% sensitivity and 92% specificity for predicting hypocalcemia.\[^3\] Similar results were shown by Sywak et al., and PTH levels predicted postoperative hypocalcemia with a sensitivity of 90% and a specificity of 84%.\[^14\] Grodski and Serpell reiterated this recommendation, reporting that postoperative PTH can be used to accurately predict the development of hypocalcemia and anticipate the need for calcium replacement.\[^5\] However, Lombardi et al. reported that PTH levels <10 pg/ml levels after surgery were unable to accurately predict hypocalcemia in 13.4% of their study population.\[^17\] In our study, 19 patients who received both calcium and Vitamin D supplementation, in spite of deficient PTH (<12 pg/ml), did not develop hypocalcemia.

Bellantone et al. reported hypocalcemia in only 11% compared to 40% of patients without calcium (3 g/day) supplementation.\[^3\] Moore reported that the use of prophylactic calcium (5g/day) alone reduced the risk of hypocalcemic crisis.\[^18\] In our study, the incidence of hypocalcemia in Group B which received only calcium supplementation is similar to Group A which did not receive supplementation \( (P = 0.189) \).

On the contrary, the Groups (C and D) which received both calcium and Vitamin D supplements had decreased incidence of hypocalcemia compared to Groups A and B \( (P = 0.001) \). Our results are similar to Roh and Park who showed that hypocalcemic symptoms were minimal in calcium and Vitamin D supplemented group but more severe in no intervention group.\[^19\] IV calcium requirement was also increased in the no intervention group, compared to oral calcium and Vitamin D group.

According to a meta-analysis by Alhefdhi et al., there was a significant decrease in the rate of symptomatic hypocalcemia.

**Table 6: Multivariate analysis of factors influencing hypocalcemia**

| Variables                  | Log OR | \( P \) | OR (95% CI)        |
|---------------------------|--------|---------|-------------------|
| Preoperative Vitamin D    | 0.312  | 0.702   | 0.743 (0.146-2.986) |
| Postoperative serum PTH   | 2.896  | <0.001  | 18.10 (4.287-45.76)  |
| Parathyroid AT            | 1.852  | <0.001  | 6.372 (2.356-18.67)  |

CI: Confidence interval, OR: Odds ratio, PTH: Parathormone, AT: Autotransplantation

**Table 7: Follow-up levels of various parameters among groups**

| Parameters                     | Group A \( (n=52) \)   | Group B \( (n=52) \)   | Group C \( (n=52) \)   | Group D \( (n=52) \)   | \( P \)  |
|-------------------------------|------------------------|------------------------|------------------------|------------------------|---------|
| Serum Ca after 3 months (mg/dL) | 9.27±0.38 (8.60-10.10) | 9.33±0.38 (8.70-10.30) | 9.22±0.28 (8.60-9.80) | 9.35±0.35 (8.90-10.00) | 0.418   |
| Serum PTH after 3 months (pg/mL) | 25.47±8.23 (3.56-42.50) | 25.04±8.05 (2.50-40.00) | 26.32±7.82 (12.33-43.00) | 26.03±7.59 (4.18-42.50) | 0.919   |
| Serum Ca after 6 months (mg/dL) | 9.24±0.45 (8.10-10.10) | 9.26±0.30 (8.70-9.80) | 9.20±0.27 (8.60-9.80) | 9.38±0.36 (8.90-10.00) | 0.193   |
| Serum PTH after 6 months (pg/mL) | 28.51±8.36 (16.00-43.20) | 27.16±7.53 (1.80-37.03) | 29.11±8.73 (17.10-43.00) | 27.01±9.67 (3.20-43.20) | 0.715   |
| Permanent hypoparathyroidism | 1/52 (1.92%)           | 2/52 (3.84%)           | 1/52 (1.92%)           | 1/52 (1.92%)           | 0.566   |

Values: Mean±SD (range). PTH: Parathormone, SD: Standard deviation, Ca: Calcium
Routine autotransplantation of at least one parathyroid gland has been proposed to prevent permanent hypoparathyroidism but results in an increased risk of postoperative transient hypocalcemia. In our study, 78.6% of patients who had parathyroid autotransplantation developed transient hypocalcemia, but none had permanent hypoparathyroidism.

The major limitation of our study is the small sample size. Recruiting more patients and a longer follow-up of 1-year duration may be useful to predict permanent hypoparathyroidism.

**CONCLUSION**

Supplementation of oral calcium and Vitamin D metabolites reduces the incidence of transient postoperative hypocalcemia and the severity of hypocalcemic symptoms. The requirement of IV calcium infusion is minimized with calcium and Vitamin D supplementation. The addition of cholecalciferol did not provide any added advantage over calcitriol. Preoperative levels of Vitamin D are not a reliable marker to predict the occurrence of hypocalcemia. Immediate autotransplantation of parathyroids results in higher incidence of temporary hypocalcemia but is effective in negating the ill effects of long-term hypocalcemia and permanent hypoparathyroidism.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Wiseman JE, Mossanen M, Ituarte PH, Bath JM, Yeh MW. An algorithm informed by the parathyroid hormone level reduces hypocalcemic complications of thyroidectomy. World J Surg 2010;34:532-7.
2. Reeve T, Thompson NW. Complications of thyroid surgery: How to avoid them, how to manage them, and observations on their possible effect on the whole patient. World J Surg 2000;24:971-5.
3. McLeod IK, Arciero C, Noordzij JP, Stojadinovic A, Peoples G, Melder PC, et al. The use of rapid parathyroid hormone assay in predicting postoperative hypocalcemia after total or completion thyroidectomy. Thyroid 2006;16:259-65.
4. Sywak MS, Palazzo FF, Yeh M, Wilkinson M, Snook K, Sidhu SB, et al. Parathyroid hormone assay predicts hypocalcaemia after total thyroidectomy. ANZ J Surg 2007;77:667-70.
5. Grodski S, Serpell J. Evidence for the role of perioperative PTH measurement after total thyroidectomy as a predictor of hypocalcemia. World J Surg 2008;32:1367-73.
6. Thomusch O, Machens A, Sekulla C, Ukkat J, Lippert H, Gastinger I, et al. Multivariate analysis of risk factors for postoperative complications in benign goiter surgery: Prospective multicenter study in Germany. World J Surg 2000;24:1335-41.
7. Abboud B, Sargi Z, Akkam M, Sleiaty F. Risk factors for postthyroidectomy hypocalcemia. J Am Coll Surg 2002;195:456-61.
8. Bellantone R, Lombardi CP, Raffaelli M, Boscherini M, Alesina PF, De Crea C, et al. Is routine supplementation therapy (calcium and Vitamin D) useful after total thyroidectomy? Surgery 2002;132:1109-12.
9. Roh JL, Park CI. Routine oral calcium and Vitamin D supplements for prevention of hypocalcemia after total thyroidectomy. Am J Surg 2006;192:675-8.
10. Kurakavecigli O, Karamerican A, Akin M, Tezel E, Ege B, Tumeri F, et al. Potential benefit of oral calcium/Vitamin D administration for prevention of symptomatic hypocalcemia after total thyroidectomy. Endocr Regul 2007;41:35-9.
11. Bilezikian JE, Marcus R, Levine M. Hypoparathyroidism in the differential diagnosis of hypocalcemia. In: The Parathyroids: Basic and Clinical Concepts. San Diego, California: Academic Press; 2001. p. 756.
12. Sasson AR, Pingpank JF Jr., Wetherington RW, Hanlon AL, Ridge JA. Incidental parathyroidectomy during thyroid surgery does not cause transient symptomatic hypocalcemia. Arch Otolaryngol Head Neck Surg 2001;127:304-8.
13. Lin DT, Patel SG, Shaha AR, Singh B, Shah JP. Incidence of inadvertent parathyroid removal during thyroidectomy. Laryngoscope 2002;112:608-11.
14. See AC, Soo KC. Hypocalcaemia following thyroidectomy for thyrotoxicosis. Br J Surg 1997;84:95-7.
15. Erbil Y, Bozbora A, Ozbey N, Issever H, Aral F, Ozarmagan S, et al. Predictive value of age and serum parathormone and Vitamin D3 levels for postoperative hypocalcemia after total thyroidectomy for non-toxic multinodular goiter. Arch Surg 2007;142:1182-7.
16. Cilia SH, Weisman RA, Tieu D, Kelly C, Dillmann WH, Orloff LA. Prospective study of perioperative factors predicting hypocalcemia after thyroid and parathyroid surgery. Arch Otolaryngol Head Neck Surg 2006;132:41-5.
17. Lombardi CP, Raffaelli M, Princi P, Dobrinja C, Carrozza C, Di Stasio E, et al. Parathyroid hormone levels 4 hours after surgery do not accurately predict post-thyroidectomy hypocalcemia. Surgery 2006;140:1016-23.
18. Moore FD Jr. Oral calcium supplements to enhance early hospital discharge after bilateral surgical treatment of the thyroid gland or exploration of the parathyroid glands. J Am Coll Surg 1994;178:11-6.
19. Rob JL, Park JY, Park CI. Prevention of postoperative hypocalcemia with routine oral calcium and Vitamin D supplements in patients with differentiated papillary thyroid carcinoma undergoing total thyroidectomy plus central neck dissection. Cancer 2009;115:251-8.
20. Alhefidi A, Mazeh H, Chen H. Role of postoperative Vitamin D and/ or calcium routine supplementation in preventing hypocalcemia after thyroidectomy: A systematic review and meta-analysis. Oncologist 2013;18:533-42.
21. Pisaniello D, Parmeggiani D, Piatto A, Avenia N, Monacelli M, et al. Which therapy to prevent post-thyroidectomy hypocalcemia? G Chir 2005;26:357-61.
22. Zedenius J, Wadstrom C, Delbridge L. Routine autotransplantation of at least one parathyroid gland during total thyroidectomy may reduce permanent hypoparathyroidism to zero. Aust N Z J Surg 1999;69:794-7.
23. Lo CY, Lam KY. Routine parathyroid autotransplantation during thyroidectomy. Surgery 2001;129:318-23.
24. Stack BC Jr., Binstrom DN, Bodemer DL, Brett EM, Drale H, Orloff LA, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Disease State Clinical Review: Postoperative hypoparathyroidism — Definitions and management. Endocr Pract 2015;21:674-85.